Rapid screening method for antisense oligonucleotides against human growth factor receptor p185(erbB-2)

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Antisense oligonucleotides (ASOs) offer therapeutic potential but require efficient screening methods.
• The human growth factor receptor p185(erbB-2) is implicated in tumor development and cell proliferation.
• Developing robust assays is crucial for identifying effective ASO drug candidates.

Purpose of the Study:

• To develop and validate an indirect cell proliferation assay for screening ASOs.
• To evaluate the biological activity of unmodified and phosphorothioate-modified oligonucleotides.
• To investigate the role of p185(erbB-2) expression in cell proliferation using specific cell lines.

Main Methods:

• Utilized BT-474 (high p185(erbB-2) expression) and MCF-7 (low p185(erbB-2) expression) cell lines.
• Transfected cells with ASOs using a liposome formulation (Lipofectin).
• Quantified cell proliferation via total protein assay (BCA method) and assessed ASO stability using a DNase I assay. Determined sequence-specific effects via Western blot.

Main Results:

• An antisense phosphorothioate oligonucleotide inhibited cell proliferation compared to control sequences.
• Oligonucleotide stability correlated with biological activity; less stable ASOs required more treatments for antiproliferative effects.
• The indirect proliferation assay proved reliable for screening ASOs targeting p185(erbB-2).

Conclusions:

• The developed indirect cell proliferation assay is a potent screening tool for antisense oligonucleotides.
• Phosphorothioate modification enhances ASO stability and biological activity.
• Targeting p185(erbB-2) with specific ASOs can inhibit cancer cell proliferation.